Publications by authors named "John M S Bartlett"

100Publications

Can immune markers help identify fast relapse in patients with muscle invasive bladder cancer?

Pathol Res Pract 2020 Nov 5;216(11):153200. Epub 2020 Sep 5.

Division of Anatomic Pathology, Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. Electronic address:

View Article and Find Full Text PDF
November 2020

Computational approaches to support comparative analysis of multiparametric tests: Modelling versus Training.

PLoS One 2020 3;15(9):e0238593. Epub 2020 Sep 3.

UCL (University College London) and National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, United Kingdom.

View Article and Find Full Text PDF
October 2020

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.

NPJ Breast Cancer 2020 12;6:17. Epub 2020 May 12.

21Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC Australia.

View Article and Find Full Text PDF
May 2020

Combining clustering and classification ensembles: A novel pipeline to identify breast cancer profiles.

Artif Intell Med 2019 06 15;97:27-37. Epub 2019 May 15.

Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, Nottingham City Hospital, University of Nottingham, Nottingham, United Kingdom.

View Article and Find Full Text PDF
June 2019

Incorporating Biology Into Breast Cancer Staging: American Joint Committee on Cancer, Eighth Edition, Revisions and Beyond.

Am Soc Clin Oncol Educ Book 2018 May;38:38-46

From the Dana-Farber Cancer Institute and Brigham and Women's Cancer Center, Boston, MA; Ontario Institute for Cancer Research, Ontario, Canada; Cancer Prevention Institute of California, Fremont, CA; Memorial Sloan Kettering Cancer Center, New York, NY.

View Article and Find Full Text PDF
May 2018

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

J Clin Oncol 2018 07 30;36(20):2105-2122. Epub 2018 May 30.

Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City, UT; Kimberly H. Allison, Stanford University School of Medicine, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, New South Wales, Australia; Ian O. Ellis, The University of Nottingham, Nottingham; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Patricia A. Spears, Cancer Information and Support Network, Raleigh, NC; Gail H. Vance, Indiana University School of Medicine, Indianapolis, IN; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.

View Article and Find Full Text PDF
July 2018

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

Arch Pathol Lab Med 2018 11 30;142(11):1364-1382. Epub 2018 May 30.

Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland; Lisa M. McShane, National Cancer Institute, Bethesda, Maryland; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City; Kimberly H. Allison, Stanford University School of Medicine, Stanford, California; Patrick Fitzgibbons, St Jude Medical Center, Fullerton, California; Michael F. Press, University of Southern California, Los Angeles; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, Virginia; John M.S. Bartlett, Ontario Institute for Cancer Research, Toronto, Ontario, Canada; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, Australia; Ian O. Ellis, The University of Nottingham, Nottingham, United Kingdom; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, Minnesota; Patricia A. Spears, Cancer Information and Support Network, Raleigh, North Carolina; Gail H. Vance, Indiana University School of Medicine, Indianapolis; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.

View Article and Find Full Text PDF
November 2018

Deregulation of the spindle assembly checkpoint is associated with paclitaxel resistance in ovarian cancer.

J Ovarian Res 2018 Apr 4;11(1):27. Epub 2018 Apr 4.

Diagnostic Development, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario, M5G 0A3, Canada.

View Article and Find Full Text PDF
April 2018

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.

J Clin Oncol 2018 04 22;36(10):981-990. Epub 2018 Feb 22.

Dimitrios Zardavas and Debora Fumagalli, Breast International Group; Christos Sotiriou, Université Libre de Bruxelles, Brussels, Belgium; Luc te Marvelde and Roger L. Milne, Cancer Council; Roger L. Milne and Sherene Loi, University of Melbourne, Melbourne; Barry Iacopetta, University of Western Australia, Western Australia; Sandra O'Toole and Elena Lopez-Knowles, Garvan Institute of Medical Research, Darlinghurst, Australia; George Fountzilas and Vassiliki Kotoula, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki; Evangelia Razis, Hygeia Hospital; George Papaxoinis, Hippokration Hospital, Athens, Greece; Heikki Joensuu, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Mary Ellen Moynahan, Memorial Sloan Kettering Cancer Center, New York, NY; Bryan T. Hennessy, Beaumont Hospital and Royal College of Surgeons, Dublin, Ireland; Ivan Bieche, Curie Institut, Paris; Thomas Bachelot, Centre de Recherche en Cancérologie de Lyon, Lyon; Stefan Michiels, Gustave Roussy and Inserm, Univ. Paris-Sud, Univ. Paris-Saclay, Villejuif, France; Lao H. Saal, Lund University, Lund; Olle Stal, Qing Wang, and Gizeh Perez-Tenorio, Linköping University, Linköping, Sweden; Jeanette Dupont Jensen, University of Southern Denmark, on behalf of the Danish Breast Cancer Cooperative Group, Odense, Denmark; Elena Lopez-Knowles, Royal Marsden NHS Trust and Institute of Cancer Research, London; Daniel W. Rea, University of Birmingham, Birmingham, United Kingdom; Mattia Barbaraeschi, Santa Chiara Hospital, Trento, Italy; Shinzaburo Noguchi, Osaka University, Osaka Japan; Hatem A. Azim Jr, American University of Beirut (AUB), Beirut, Lebanon; Enrique Lerma, Universitat Autònoma de Barcelona, Barcelona, Spain; Cornelis J.H. can de Velde, Leiden University Medical Center, Leiden, the Netherlands; Vicky Sabine, University of Guelph, Guelph; John M.S. Bartlett, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

View Article and Find Full Text PDF
April 2018

Toward Biological Subtyping of Papillary Renal Cell Carcinoma With Clinical Implications Through Histologic, Immunohistochemical, and Molecular Analysis.

Am J Surg Pathol 2017 Dec;41(12):1618-1629

*Department of Laboratory Medicine, and the Keenan Research Centre for Biomedical Science at the Li Ka Shing Knowledge Institute, St. Michael's Hospital †Department of Laboratory Medicine and Pathobiology, University of Toronto ∥Department of Pathology **Division of Medical Oncology and Hematology, Sunnybrook Health Sciences Centre ¶Department of Surgery, Division of Urology, St. Michael's Hospital #Department of Pathology, University Health Network ††Ontario Institute for Cancer Research, Toronto, ON Departments of ‡Pathology §Urology, McGill University Health Center, Montreal, QC, Canada.

View Article and Find Full Text PDF
December 2017

ISOWN: accurate somatic mutation identification in the absence of normal tissue controls.

Genome Med 2017 06 29;9(1):59. Epub 2017 Jun 29.

Informatics and Bio-computing, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

View Article and Find Full Text PDF
June 2017

Breast cancers are rare diseases-and must be treated as such.

NPJ Breast Cancer 2017 11;3:11. Epub 2017 Apr 11.

Canadian Clinical Trials Group, Queen's University, Kingston, Ontario Canada.

View Article and Find Full Text PDF
April 2017

Reliability and performance of commercial RNA and DNA extraction kits for FFPE tissue cores.

PLoS One 2017 22;12(6):e0179732. Epub 2017 Jun 22.

Department of Pathology & Molecular Medicine, Queen's University, Kingston, Ontario, Canada.

View Article and Find Full Text PDF
September 2017

Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.

Eur J Cancer 2017 09 11;82:219-227. Epub 2017 Mar 11.

BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, The Netherlands; Department of Pathology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address:

View Article and Find Full Text PDF
September 2017

EMT in Breast Carcinoma-A Review.

J Clin Med 2016 Jul 14;5(7). Epub 2016 Jul 14.

Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada.

View Article and Find Full Text PDF
July 2016

Tumour sampling method can significantly influence gene expression profiles derived from neoadjuvant window studies.

Sci Rep 2016 07 7;6:29434. Epub 2016 Jul 7.

Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.

View Article and Find Full Text PDF
July 2016

Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others.

J Natl Cancer Inst 2016 09 29;108(9). Epub 2016 Apr 29.

Ontario Institute for Cancer Research, Toronto, Ontario, Canada (JMSB, JB); University of Toronto, Toronto, Canada (JMSB); University of Edinburgh, Edinburgh, UK (JMSB, CC, MSS, PSH, DAC); Warwick Clinical Trials Unit, University of Warwick, Coventry, UK (AM, JAD, AC); University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK (CJP); University of Cambridge Department of Oncology and NIHR Cambridge Biomedical Research Centre, Cambridge, UK (HME); Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham, UK (DWR); University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK (IRM, PC); University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK (AF); University of Alberta, Edmonton, AB, Canada (CM); Kings College London, Guy's Hospital, London, UK (SEP); Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK (LHD); Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, Middlesex, UK (AM); National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, UK (RCS).

View Article and Find Full Text PDF
September 2016

Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial.

Arch Pathol Lab Med 2016 Jan;140(1):66-74

From the Transformative Pathology Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada (Dr Bartlett); Biomarker and Companion Diagnostic Group, Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, United Kingdom (Dr Bartlett and Ms Piper); Research and Development (Dr Christiansen) and Medical Affairs (Dr Gustavson), Genoptix, Inc, Carlsbad, California; the Department of Pathology, Yale University School of Medicine, New Haven, Connecticut (Dr Rimm); the Departments of Surgery (Dr van de Velde) and Medical Statistics and Bioinformatics (Dr Putter), Leiden University Medical Center, Leiden, The Netherlands; the Department of Gynecological Oncology, University Medical Center Freiburg, Freiburg, Germany (Dr Hasenburg); the Department of Obstetrics and Gynecology, Elblandklinikum, Riesa, Germany (Dr Kieback); the Department of Surgery, Athens University Medical School, Athens, Greece (Dr Markopoulos); Oncology Center, Sint-Augustinus, Wilrijk-Antwerp, Belgium (Dr Dirix); the Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands (Dr Seynaeve); and Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom (Dr Rea). Dr Christiansen is now with Diagnostic Development at Ignyta, Inc, San Diego, California. Dr Gustavson is now with Diagnostics Department at MetaStat, Inc, Boston, Massachusetts. Dr Kieback is now with the Department of Obstetrics and Gynecology at Klinikum Vest Medical Center, Marl, Germany.

View Article and Find Full Text PDF
January 2016

Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.

J Clin Oncol 2015 May 20;33(15):1680-7. Epub 2015 Apr 20.

John M.S. Bartlett, Ontario Institute for Cancer Research; Frances P. O'Malley, St Michael's Hospital; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre and University of Toronto, Toronto; John M.S. Bartlett, Frances P. O'Malley, and Lois E. Shepherd, National Cancer Institute of Canada Clinical Trials Group; Lois E. Shepherd, Queen's University, Kingston, Canada; John M.S. Bartlett, Alison F. Munro, and David A. Cameron, University of Edinburgh, Edinburgh; Christopher C. McConkey, Janet A. Dunn, and Christopher J. Poole, University of Warwick, Coventry; Helena M. Earl and Carlos Caldas, University of Cambridge, Cambridge; Christopher J. Twelves, St James's University Hospital, Leeds; Daniel W. Rea, University of Birmingham, Birmingham, United Kingdom; Christine Desmedt and Denis P. Larsimont, Université Libre de Bruxelles, Brussels, Belgium; Fatima Cardoso, Champalimaud Cancer Centre, Lisbon, Portugal; Maj-Britt Jensen and Bent Ejlertsen, Rigshospitalet, Copenhagen, Denmark; and Angelo Di Leo, Hospital of Prato, Prato, Italy.

View Article and Find Full Text PDF
May 2015

Updated UK Recommendations for HER2 assessment in breast cancer.

J Clin Pathol 2015 Feb 8;68(2):93-9. Epub 2014 Dec 8.

Department of Pathology, University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, UK.

View Article and Find Full Text PDF
February 2015

Validated or not validated? That is the question.

J Natl Cancer Inst 2014 Jan;106(1):djt360

Affiliations of authors: Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada (JMSB, MS); Edinburgh Cancer Research UK Centre, University of Edinburgh, Edinburgh, UK (JMSB); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada (JMSB); Institute of Health Policy Management and Evaluation, University of Edinburgh, Toronto, ON, Canada (KIP); Sunnybrook Odette Cancer Centre, Toronto, ON, Canada (KIP).

View Article and Find Full Text PDF
January 2014

Ductal carcinoma in situ of the breast: can biomarkers improve current management?

Clin Chem 2014 Jan 21;60(1):60-7. Epub 2013 Nov 21.

Ontario Institute for Cancer Research, Toronto, ON, Canada;

View Article and Find Full Text PDF
January 2014

An international Ki67 reproducibility study.

J Natl Cancer Inst 2013 Dec 7;105(24):1897-906. Epub 2013 Nov 7.

Affiliations of authors: Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (MCP, LMM); Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada (SCYL, DG, EM, TON); Department of Laboratory Medicine and Pathology, University of Alberta, Alberta, Canada (JCH); Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy (MGM); Division of Pathology and Laboratory Medicine, European Institute of Oncology, and University of Milan, Milan, Italy (GV); Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom (LAZ); Department of Pathology, Centre Jean Perrin, Clermont-Ferrand, and Université d'Auvergne, France (FP-L); Transformative Pathology, Ontario Institute for Cancer Research, Toronto, Ontario, Canada (JMSB); PhenoPath Laboratories, Seattle, WA (AMG); Department of Pathology, MD Anderson Cancer Center, Houston, TX (WFS); Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom (TP); The EMMES Corporation, Rockville, MD (RAE); Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI (DFH); Academic Department of Biochemistry, Royal Marsden Hospital, London, United Kingdom (MD); on behalf of the International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group.

View Article and Find Full Text PDF
December 2013

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

J Clin Oncol 2013 Nov 7;31(31):3997-4013. Epub 2013 Oct 7.

Antonio C. Wolff, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth H. Hammond, University of Utah School of Medicine and Intermountain Healthcare, Salt Lake City, UT; David G. Hicks, University of Rochester Medical Center, Rochester, NY; Mitch Dowsett, Royal Marsden Hospital, London, United Kingdom; Kimberly H. Allison, Stanford University Medical Center, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Donald C. Allred, Washington University School of Medicine, St Louis, MO; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Michael Bilous, University of Western Sydney and Healthscope Pathology, Sydney, New South Wales, Australia; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Patricia A. Spears, North Carolina State University, Raleigh, NC; Gail H. Vance, Indiana University Medical Center, Indianapolis, IN; Giuseppe Viale, University of Milan, European Institute of Oncology, Milan, Italy; and Daniel F. Hayes, University of Michigan Comprehensive Cancer Care Center, Ann Arbor, MI.

View Article and Find Full Text PDF
November 2013

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Arch Pathol Lab Med 2014 Feb 7;138(2):241-56. Epub 2013 Oct 7.

Antonio C. Wolff, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth H. Hammond, University of Utah School of Medicine and Intermountain Healthcare, Salt Lake City, UT; David G. Hicks, University of Rochester Medical Center, Rochester, NY; Mitch Dowsett, Royal Marsden Hospital, London, United Kingdom; Kimberly H. Allison, Stanford University Medical Center, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Donald C. Allred, Washington University School of Medicine, St Louis, MO; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Michael Bilous, University of Western Sydney and Healthscope Pathology, Sydney, New South Wales, Australia; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project, Pitsburgh, PA; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Patricia A. Spears, North Carolina State University, Raleigh, NC; Gail H. Vance, Indiana University Medical Center, Indianapolis, IN; Giuseppe Viale, University of Milan, European Institute of Oncology, Milan, Italy; and Daniel F. Hayes, University of Michigan Comprehensive Cancer Care Center, Ann Arbor, MI.

View Article and Find Full Text PDF
February 2014

HER2 testing: current status and future directions.

Cancer Treat Rev 2014 Mar 11;40(2):276-84. Epub 2013 Sep 11.

Mayo Clinic, 4500 San Pablo Rd., Jacksonville, FL 32224, USA. Electronic address:

View Article and Find Full Text PDF
March 2014

Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer.

Breast Cancer Res Treat 2013 Apr 28;138(3):773-81. Epub 2013 Mar 28.

Ontario Institute for Cancer Research, MaRS Centre, South Tower, 101 College Street, Suite 800, Toronto, ON M5G 0A3, Canada.

View Article and Find Full Text PDF
April 2013

Interactions between MAP kinase and oestrogen receptor in human breast cancer.

Eur J Cancer 2013 Apr 19;49(6):1176-86. Epub 2012 Dec 19.

Institute of Cancer Sciences, College of MVLS, University of Glasgow, Western Infirmary, Glasgow G11 6NT, UK.

View Article and Find Full Text PDF
April 2013

DNA repair and replication proteins as prognostic markers in melanoma.

Histopathology 2013 Jan 28;62(2):343-50. Epub 2012 Sep 28.

Edinburgh Cancer Research Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, Scotland, UK.

View Article and Find Full Text PDF
January 2013

GSK3β and cyclin D1 expression predicts outcome in early breast cancer patients.

Breast Cancer Res Treat 2012 Nov 14;136(1):161-8. Epub 2012 Sep 14.

Endocrine Cancer Group, Edinburgh University, Edinburgh, UK.

View Article and Find Full Text PDF
November 2012

Validation of tissue microarrays in oral epithelial dysplasia using a novel virtual-array technique.

J Clin Pathol 2012 Dec 22;65(12):1084-7. Epub 2012 Aug 22.

School of Cancer Studies, Institute of Head and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, UK.

View Article and Find Full Text PDF
December 2012

Expression of activated type I receptor tyrosine kinases in early breast cancer.

Breast Cancer Res Treat 2012 Jul 5;134(2):701-8. Epub 2012 May 5.

Transformative Pathology, Ontario Institute for Cancer Research, MaRS Centre, South Tower, 101 College St, Suite 800, Toronto, ON, M5G 043, Canada.

View Article and Find Full Text PDF
July 2012

Proximity ligation assays for isoform-specific Akt activation in breast cancer identify activated Akt1 as a driver of progression.

J Pathol 2012 Aug 30;227(4):481-9. Epub 2012 Apr 30.

Transformative Pathology, Ontario Institute for Cancer Research, MaRS Centre, South Tower, 101 College St, Suite 800, Toronto, Ontario, Canada M5G 043.

View Article and Find Full Text PDF
August 2012

Relative impact of key sources of systematic noise in Affymetrix and Illumina gene-expression microarray experiments.

BMC Genomics 2011 Dec 1;12:589. Epub 2011 Dec 1.

Applied Bioinformatics of Cancer Group, Breakthrough Breast Cancer Research Unit, Institute of Genetics and Molecular Medicine, Crewe Road South, Edinburgh, Edinburgh, EH4 2XR, UK.

View Article and Find Full Text PDF
December 2011

Association of galectin-3 expression with melanoma progression and prognosis.

Eur J Cancer 2012 Apr 7;48(6):865-74. Epub 2011 Nov 7.

Edinburgh Cancer Centre, NHS Lothian, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK.

View Article and Find Full Text PDF
April 2012

Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial.

Breast Cancer Res Treat 2012 Jan 1;131(2):541-51. Epub 2011 Nov 1.

Sunnybrook Odette Cancer Centre, The University of Toronto, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada.

View Article and Find Full Text PDF
January 2012

In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer.

Breast Cancer Res Treat 2012 Apr 3;132(2):463-70. Epub 2011 Jun 3.

Edinburgh Breakthrough Breast Cancer Unit, Edinburgh Cancer Research Centre, Western General Hospital, Crewe Road South, Edinburgh EH4 2XR, UK.

View Article and Find Full Text PDF
April 2012